Drug intelligence / Profile preview

Tong Luo Hua Shi Capsules

Development stage: Unknown
Lead developer: First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Administration: Oral

Overview

Tong Luo Hua Shi Capsules is a Traditional Chinese Medicine (TCM) botanical product developed by The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine for the treatment of rheumatoid arthritis. In TCM theory, the formulation is intended to 'unblock collaterals' (Tong Luo) and 'resolve dampness' (Hua Shi), addressing the underlying 'Bi syndrome' associated with joint inflammation and pain. It has been evaluated in Phase II clinical trials in China, both as a standalone treatment and alongside conventional therapies such as leflunomide and diclofenac.

Other names: Tongluo Huashi Capsules

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on Tong Luo Hua Shi Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tong Luo Hua Shi Capsules.

Explore the full profile